The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biovex.com

Founded Year

1997

Stage

Acquired | Acquired

Total Raised

$155.36M

Valuation

$0000 

Revenue

$0000 

About BioVex

BioVex is a biotechnology company that develops vaccines. The company develops vaccines for the treatment of cancer and chronic infectious diseases. BioVex has two proprietary vaccine platforms; OncoVEX and ImmunoVEX, and a functional genomics platform for gene target validation in neurons and other tissues.

BioVex Headquarter Location

34 Commerce Way

Woburn, Massachusetts, 01801,

United States

781-933-1409

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioVex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioVex is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

BioVex Patents

BioVex has filed 10 patents.

The 3 most popular patent topics include:

  • Animal viral diseases
  • Animal virology
  • Viral diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/7/2014

5/28/2019

Biotechnology, Molecular biology, Virology, Transcription factors, Cytokines

Grant

Application Date

2/7/2014

Grant Date

5/28/2019

Title

Related Topics

Biotechnology, Molecular biology, Virology, Transcription factors, Cytokines

Status

Grant

Latest BioVex News

Worldwide Oncolytic Virus Immunotherapy Industry to 2026 - Featuring BioVex, Cell Genesys & Crusade Laboratories Among Others

Oct 23, 2020

News provided by Share this article As per this reports findings, it is estimated that the total inflation of the market with respect to clinical platform, wider acceptance in a short period of time will drive the market in the upcoming years. Gradual increase in the interest of the researchers towards oncolytic virus therapy will develop the market which will eventually bring complete revolution in terms of applications to the cancer patients. The future market insight for the therapy is analyzed to provide unlimited number of trends and opportunities, leading to aggregation of all the cancer related bio-pharmaceutical companies and research centers towards the further development and commercialization of the therapy. Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026 Report Highlights: Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials Comprehensive Insight on Clinical & Non Clinical Issues Related to Global Oncolytic Virus Immunotherapy Market Development Approved Oncolytic Virus Immunotherapy: 2 Global Research Progress & Medical Advancement Insight Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight Increase in prevalence and mortality rate associated with cancer has always remained a challenge to the modern medicine with respect to the development of more reliable therapies. In the past few years, one of the greatest breakthrough novel cancer therapy that has been developed by the researchers is the oncolytic virus immunotherapy. The overall procedure of the therapy is based on the ability of the oncolytic virus to infect and further lyse the tumor cells by boosting the immune system of the patient. Some of the virus strains that have been tested and proved to be adding to the various applications of the therapy are canine distemper virus, adenovirus, vaccinia virus and reovirus in the preclinical and clinical studies. The undefined applications of using virus for the cancer treatment and the in-vitro manipulation of the virus with respect to cancer micro environment are estimated to be providing successful clinical outcomes at preclinical and clinical level, thus leading to the enhancement and the expansion of the market. All the clinical trials associated with the therapy are boosted with the available drivers as all concerned drivers are estimated to bring forward numerous opportunities for the cancer patients. The market concerned with the growth of the oncolytic virus therapy is also focused on increasing the research and development sector activities. The market within no time is estimated to be recognized as an important asset for the cancer therapeutics as it carries the ability to change the stringent cancer treatment paradigm available for the patients. The current clinical platform is estimated to be developing a competitive landscape for the other cancer markets as it is getting fragmented at a high speed when compared with other cancer therapies status. The blockbuster model held by the therapy is also believed to be driving the large shareholder value of the market in the present as well as in the upcoming years. The increase in the perception of highly expensive drugs available under cell and gene therapy are expected to be one of the most regulated drivers for the global expansion of the oncolytic therapy. As a result of strong clinical background and healthy research and development sector, oncolytic virus therapy is becoming more prominent in the cancer landscape. With the primary goal of revolutionizing the cancer therapeutics market, it is estimated that the therapy in a short period of time will be successful in re-defining the unstructured cancer paradigm for the patients with advanced cancers. Being not only restricted to clinical benefits, the therapy is moving forward to provide better post-treatment lives to the cancer patients. The therapy in the clinical studies have been able to put forward the value of the patients in terms of clinical outcomes as well as patient-related outcome measures, thus causing a wider acceptance to the therapy in the cancer therapeutics market. Some of the primary aim associated with the current clinical pipeline of the therapy involves limited cost expansion and increased success rate. Prominent factors like these are estimated to enhance access of the patient population to effective oncolytic virus therapy. The future view of the oncolytic virus therapy is estimated to be enabling such innovative mechanisms that would be responsible for providing tremendous amount of opportunities to the cancer patients. Different gene-editing technologies, advancement in genomics and many others will map the therapy among the best-cancer regimens ever discovered. The leverage provided to the therapy in terms of opportunities depicts the possibility of the therapy to get recognized as a real cure to the cancer patients and eventually a dominating market. With the advent of the therapy for the cancer platform, there has been a significant transformation in the current cancer therapeutics market. In financial services, the market is estimated to perform with accuracy and speed in the future years. Key Topics Covered: 1.1 Outline of Oncolytic Virotherapy 1.2 Trail from Genesis to Biogenetics 2. Primer of Virotherapy in Malignancies 2.1 Oncolytic Viruses towards Cancer 2.2 Approaches for Targeting Tumor Cells 2.2.1 Pro Apoptotic Targeting 10.1 Oncolytic Virus Therapy Development as a Cancer Vaccine 10.2 Oncolytic Virus Therapy Collaboration with T-Cell Therapy for Advanced Results 10.3 Preliminary Effectiveness of Oncolytic Virus Therapy in Killing Malignant Tumor Cells in Children 10.4 Combined Study of Oncolytic Virus Therapy and CAR-T Cell Therapy by City of Hope Researchers 10.5 TG4001 & TG6002 Positive Clinical Results against HPV-Induced Cancers 10.6 Pelareorep-Anti-PD-1 Combination for the Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer 10.7 Adenovirus E3 Region to Substantially Improve Oncolytic Efficacy & Potency 10.8 University of Helsinki Novel Solution for Advancing Oncolytic Virus Therapy 10.9 Valo Therapeutics Technology Acquisition for Advancing Oncolytic Therapy 10.10 Mayo Clinic to Expand Oncolytic Virus Therapy against Multiple Myeloma 11. Strategic Partnership & Collaborations to Advance the Oncolytic Virus Therapy Market 11.1 Mustang Bio & Nationwide Children's Hospital to Undergo Collaboration for Oncolytic Virus Therapy for Glioblastoma 11.2 Pfizer & Western Oncolytics Collaboration Announcement for Novel Oncolytic Treatment 11.3 Tessa Therapeutics & Vyriad to Synergistically Boost the Novel Oncolytic Treatment 11.4 Boehringer Ingelheim & Vira Therapeutics to Develop Next Generation Oncolytic Virus Therapy for the Cancer Patients 11.5 Regeneron & Vyriad Therapeutics Collaboration for Unravelling Oncoytic Virus Therapy for Cancer Treatment 11.6 DNAtrix & Valo Therapeutics Collaboration for Evaluating Peptide Based Oncolytic Therapy for the Cancer Patients 11.7 Pfizer & Ignite Immunotherapy to Collaboration for Developing Next-Generation Oncolytic Virus Therapy 11.8 AbbVie & Turnstone Biologics to Collaborate for Next-Generation Oncolytic Viral Immunotherapies 11.9 ABL Europe & SillaJen to Expand Oncolytic Virus Therapy Market 11.10 PsiOxus & BMS Ink Collaboration for the Development of Transgenic Oncolytic Therapy 12. Global Oncolytic Virus Immunotherapy Clinical Trials By Company, Indication & Phase 12.1 Research

You May Also Like

Z
Zetra Biologicals

Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

H
Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.

N
Nabi Biopharmaceuticals

has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.